World's Best Scientists 2026 revealed!
Ramón García-Sanz

Ramón García-Sanz

D-Index & Metrics

Medicine

D-Index
90
Citations
30232
World Ranking
12195
National Ranking
172

Ramón García-Sanz publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Ramón García-Sanz sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 548 publications — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Ramón García-Sanz D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Ramón García-Sanz sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Ramón García-Sanz is affiliated with the University of Salamanca in Spain. Their research is situated primarily within the field of Medicine, with a focused expertise in Hematology. The scientist has contributed extensively to subfields including Genetics, Pathology and Forensic Medicine, Oncology, and Immunology.

The research topics covered by Ramón García-Sanz center on various aspects of hematological diseases and treatments. Main topics include:

  • Lymphoma Diagnosis and Treatment
  • Chronic Lymphocytic Leukemia Research
  • Multiple Myeloma Research and Treatments
  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Immunodeficiency and Autoimmune Disorders
  • Protein Degradation and Inhibitors

Their publication record features numerous articles in prominent scientific journals. Frequent venues for publication consist of:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Hematological Oncology
  • HemaSphere
  • Blood Advances

Noteworthy recent papers include:

  • A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study (2020), published in Blood
  • COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) (2021), published in Journal of Hematology & Oncology
  • Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group (2021), published in The Lancet Oncology
  • A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma (2020), published in Blood
  • Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma (2020), published in Blood

Ramón García-Sanz has collaborated extensively with a core group of scientific co-authors. Frequent co-authors include:

  • Joaquin Martínez-López
  • Noemí Puig
  • María-Victoria Mateos
  • Carmen Chillón
  • Jesús F. San Miguel

Best Publications

  • Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.

    J J M van Dongen;A W Langerak;M Brüggemann;P A S Evans

  • Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma

    J Flores-Montero;L Sanoja-Flores;B Paiva;N Puig

  • New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells

    Ernesto Pérez-Persona;María-Belén Vidriales;Gema Mateo;Ramón García-Sanz

  • Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

  • Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

    María-Victoria Mateos;María-Victoria Mateos;José-M. Hernández;José-M. Hernández;Miguel-T. Hernández;Miguel-T. Hernández;Norma-C. Gutiérrez;Norma-C. Gutiérrez

  • International prognostic scoring system for Waldenstrom macroglobulinemia

    Pierre Morel;Alain Duhamel;Paolo Gobbi;Meletios A. Dimopoulos

  • Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Joaquin Martinez-Lopez;Juan J. Lahuerta;François Pepin;Marcos González

  • Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics

    R. Garcı́a-Sanz;A. Orfão;M. González;M.D. Tabernero

  • International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

    Evangelos Terpos;Gareth Morgan;Meletios Athanasios Dimopoulos;Matthew T. Drake

  • Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

    Noopur Raje;Evangelos Terpos;Wolfgang Willenbacher;Kazuyuki Shimizu

  • International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

    Jens Hillengass;Saad Usmani;S Vincent Rajkumar;Brian G M Durie

  • A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.

    Constantine S. Tam;Stephen Opat;Shirley D'Sa;Wojciech Jurczak

  • A primitive hematopoietic cell is the target for the leukemic transformation in human Philadelphia-positive acute lymphoblastic leukemia

    C Cobaleda;N Gutiérrez-Cianca;J Pérez-Losada;T Flores

  • Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis.

    Maria E. Sarasquete;Ramon García-Sanz;Luis Marín;Miguel Alcoceba

  • Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia

    Meletios A. Dimopoulos;Alessandra Tedeschi;Judith Trotman;Ramón García-Sanz

  • Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms.

    Brian A Walker;Christopher P Wardell;Lorenzo Melchor;Annamaria Brioli

  • Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

    Roger G. Owen;Robert A. Kyle;Marvin J. Stone;Andy C. Rawstron

  • Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.

    M. Ocqueteau;A. Orfao;J. Almeida;J. Bladé

  • Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

    Ramón García‐Sanz;Silvia Montoto;Agustín Torrequebrada;Alfonso García De Coca

  • Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

    María-Victoria Mateos;Albert Oriol;Joaquín Martínez-López;Norma Gutiérrez

Frequent Co-Authors

Jesús F. San Miguel
Jesús F. San Miguel University of Navarra
Marcos González
Marcos González University of Salamanca
Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Juan José Lahuerta
Juan José Lahuerta Complutense University of Madrid
Joan Bladé
Joan Bladé University of Barcelona
Albert Oriol
Albert Oriol Autonomous University of Barcelona
Alberto Orfao
Alberto Orfao University of Salamanca
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
David Gonzalez
David Gonzalez University of California, San Diego
Steven P. Treon
Steven P. Treon Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens doors to a wide range of healthcare careers. For those interested in leadership or the business side of healthcare, a healthcare administration associate degree online can provide foundational skills for managing clinics or hospitals.

Nurses seeking better opportunities may consider adn to np programs online. These bridge programs are ideal for registered nurses with an associate degree, allowing them to advance to a nurse practitioner role more efficiently.

Interested in diet, wellness, or preventive care? Accredited online nutrition degree programs prepare students for roles in health education, food service management, or even community outreach.

For those aiming for high-level leadership, the best mha programs offer advanced, CAHME-accredited online degrees focused on healthcare administration and policy.

Whether your interests lie in direct patient care, management, or public health, these online degree options provide flexible pathways to diverse careers within the US healthcare system.

Best Scientists Citing Ramón García-Sanz

Trending Scientists

Recently Published Articles